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Stable Foxp3 expression is crucial for regulatory T
(Treg) cell function. We observed that antigen-driven
activation and inflammation in the CNS promoted
Foxp3 instability selectively in the autoreactive Treg
cells that expressed high amounts of Foxp3 before
experimental autoimmune encephalitis induction.
Treg cells with a demethylated Treg-cell-specific
demethylated region in the Foxp3 locus downregu-
lated Foxp3 transcription in the inflamed CNS during
the induction phase of the response. Stable Foxp3
expression returned at the population level with the
resolution of inflammation or was rescued by IL-
2-anti-IL-2 complex treatment during the antigen
priming phase. Thus, a subset of fully committed
self-antigen-specific Treg cells lost Foxp3 expres-
sion during an inflammatory autoimmune response
and might be involved in inadequate control of auto-
immunity. These results have important implications
for Treg cell therapies and give insights into the
dynamics of the Treg cell network during autoreac-
tive CD4+ T cell effector responses in vivo.
INTRODUCTION
CD4+CD25+Foxp3+ regulatory T (Treg) cells are crucial for self-
tolerance and for maintaining balanced immune responses.
Reduced numbers or function of Treg cells have been associ-
ated with the onset of autoimmunity (Long and Buckner, 2011;
Tang et al., 2008), whereas increasing the number of Treg cells
has had therapeutic success in models of autoimmunity and
graft-versus-host disease (GVHD). In fact, Treg-cell-based ther-
apies are currently being tested in clinical trials (Brunstein et al.,
2011; http://clinicaltrials.gov/ct2/show/NCT01210664?term=
type+1+diabetes+and+tregcells&rank=1). Treg cells constitu-
tively express interleukin-2 (IL-2) receptor (IL-2R) and dependIon IL-2 for survival and homeostasis in the periphery (Burchill
et al., 2008; Cheng et al., 2011). Treg cells have attributes of acti-
vated conventional T (Tconv) cells with constitutively activated
T cell receptor (TCR) signaling pathways and uncommitted chro-
matin marks onmany ‘‘T effector’’ gene loci, such as interferon-g
(IFN-g) (Moran et al., 2011; Salomon et al., 2000; Wei et al.,
2009). The Treg cell transcription factor Foxp3 activates genes
required for suppressor function and is essential for maintaining
the transcriptional program of the Treg cell lineage (Gavin et al.,
2007). In fact, targeted deletion of Foxp3 in Treg cells turns them
into IFN-g- or IL-2-producing T effector cells (Williams and
Rudensky, 2007). In this regard, Treg cells deficient in single
transcription factors or key signaling proteins have identified
pathways crucial for Foxp3 expression and stability (Kitoh
et al., 2009; Rudra et al., 2009; Vanvalkenburgh et al., 2011;
Wang et al., 2011; Yao et al., 2007; Zanin-Zhorov et al., 2010;
Zheng et al., 2010). These studies support the general concept
that altered signaling can lead to Treg cell instability and the pos-
sibility that at least a subset of Treg cells could be unstable and
lose Foxp3 expression once the cell lineage is fully established.
We, as well as others, have shown that a substantial subset of
unmanipulated CD4+ T cells express low levels of Foxp3 in vivo,
especially in lymphopenic and inflammatory settings (Zhou et al.,
2009; Miyao et al., 2012). With the use of lineage reporter and
tracer mice for characterizing loss of Foxp3 expression and
concomitant functional activity (Rubtsov et al., 2010; Sharma
et al., 2010; Zhou et al., 2009), it was observed that Treg cell
instability results in loss of the regulatory network that maintains
self-tolerance. Additionally, cells that downregulate Foxp3
expression (‘‘exFoxp3’’ cells) produce proinflammatory cyto-
kines and can act as effector cells causing tissue destruction if
they are self-reactive (Zhou et al., 2009), a characteristic of
thymically derived Treg (tTreg) cells (Hsieh et al., 2006; Wong
et al., 2007). Thus, the emergence of effector-cell-like character-
istics in this population could have serious repercussions for
autoimmunity in terms of both loss of regulation and potential
pathogenic activity.
More recent studies have argued that many, if not all, of these
exFoxp3 cells derive from an early, ‘‘aborted’’ T cell differentia-
tion process that occurs prior to full Treg cell commitment rathermmunity 39, 949–962, November 14, 2013 ª2013 Elsevier Inc. 949
Immunity
Treg Cell Instability during Autoimmune Attackthan from the instability of bona fide tTreg cells (Rubtsov et al.,
2010; Miyao et al., 2012). These studies were conducted under
largely homeostatic conditions in the steady state, in vitro, or
the setting of acute lymphopenia, thus raising the question of
whether the Treg cell instability observed by us and others could
be related to the inflammatory pathogenic setting in our studies.
Indeed, a number of reports have demonstrated Treg cell
reprogramming and acquisition of pathogenic potential in auto-
immunity, GVHD, and vaccination settings (Dominguez-Villar
et al., 2011; Laurence et al., 2012; McClymont et al., 2011;
Sharma et al., 2010; Zhou et al., 2009), consistent with the sug-
gestion that active immunity might have direct effects on Treg
cell stability. Therefore, in this study, we set out to examine
Foxp3 stability in bona fide Foxp3hi Treg cells responding to
self-antigen within a polyclonal T cell repertoire and in the
context of an active CD4+ T cell autoimmune response. Using
an experimentally induced autoimmune encephalomyelitis
(EAE) model, we observed that antigen-driven activation and
inflammation promoted Foxp3 instability selectively in the autor-
eactive Treg cells that expressed high levels of Foxp3 before
EAE induction. Transfer experiments demonstrated that bona
fide Treg cells with a demethylated Treg-cell-specific demethy-
lated region (TSDR) in the Foxp3 locus downregulated Foxp3
transcription during the induction phase of the response. Stimu-
lation with cognate autoantigen induced IFN-g production by the
exFoxp3 cells in the CNS at the peak of the response. Stable
Foxp3 expression returned with the resolution of inflammation
or was rescued by enhancement of IL-2 receptor signaling with
IL-2-anti-IL-2 complex treatment during the antigen priming
phase. These findings suggest that a subset of antigen-specific
Treg cells participating in the control of an immune response can
be reprogrammed and might play a role as potentially patho-
genic cells during autoimmunity.
RESULTS
Unstable Foxp3 Expression during EAE in C57BL/6Mice
Treg cells were analyzed in EAE induced in the C57BL/6 (B6)
genetic background. The previously described Foxp3-lineage
reporter mice (Zhou et al., 2009) were backcrossed more than
eight generations onto theB6 background. In these bacterial arti-
ficial chromosome (BAC) transgenic mice, Foxp3 promoter and
regulatory elements drive the Cre-recombinase-GFP fusion pro-
tein. These mice were bred to two different independent mouse
strains that express either a yellow fluorescent protein (YFP) or a
red fluorescent protein (RFP) transgene engineered with a stop
codon flanked by loxP sites and inserted into the Rosa26 locus.
In the dual-expressing (Foxp3.GFP-Cre and Rosa26.YFP or
Rosa26.RFP) reporter mice, any cell expressing Foxp3 ex-
presses RFP or YFP for its lifetime, whereas GFP is expressed
only in cells that currently express Foxp3. The CD4+ T cell
compartment of 6- to 8-week-old B6 Foxp3-Cre BAC transgenic
mice crossed to Rosa26.RFP mice contained 0.5%–1.5% CD4+
T cells with reduced or lost Foxp3 expression (termed exFoxp3
cells; Figure 1A) in the steady state. These data were confirmed
in another line of B6 mice generated with Cre recombinase ex-
pressed in the Foxp3 30 UTR (Rubtsov et al., 2008) and crossed
to Rosa26.RFP mice (Figure S1, available online). These results
demonstrate that Foxp3 downregulation occurred within the950 Immunity 39, 949–962, November 14, 2013 ª2013 Elsevier Inc.polyclonal Treg cell population in a lymphoreplete, intact immune
environment, albeit in a small percentage of the cells.
Next, we induced EAE by immunizing B6 mice with MOG35-55
peptide in complete Freund’s adjuvant (CFA) (MOG35-55-CFA).
Lymphocytes were harvested from the draining lymph nodes
(LNs) and spleen and CNS tissues of immunized mice and
were examined for evidence of antigen-specific T cell expansion
and differentiation with a major histocompatibility complex
(MHC)-peptide tetramer, I-Ab-MOG38-49, which bound to
MOG35-55-peptide-specific T cells as previously described
(Korn et al., 2007). Using this probe, we analyzed MOG38-49-
specific CD4+ T cells among the polyclonal CD4+ T cell popula-
tion during the asymptomatic and inflammatory phases of
MOG35-55-induced EAE. After an enrichment step, MOG38-49-
reactive cells accounted for 4% of CD4+ T cells in the peripheral
T cell compartment after EAE induction (Figure 1B). The tetramer
staining was specific given that control I-Ab:hClip tetramer stain-
ing was negligible in this population (data not shown). For further
studies, we focused on an analysis of antigen-specific T cells
within polyclonal populations.
Initial studies showed that there was virtually no detectable
I-Ab:MOG38-49 tetramer
+CD4+ T cells (0.2% of CD4+ T cells after
an enrichment step in vitro for tetramer-bound cells) in the LNs
prior to immunization (data not shown). Thus, after immunization,
MOG38-49-specific CD4
+ T cells expanded in draining LNs and
spleen and expressed CD44, indicative of antigen-driven activa-
tion. During the clinical phases of EAE, all CD4+ T cells in theCNS
expressed high amounts of the activation marker CD44, and
MOG38-49-specific cells accumulated and represented >4% of
CD4+ T cells in the CNS (without any enrichment step in vitro,
as required for seeing the cells in the draining LNs) (Figure 1B).
We assayed the ‘‘quality’’ of the self-antigen-specific Treg cells
during an autoimmune response by tracing the kinetics of Treg
cells during EAE and the stability of Foxp3 expression with
lineage-traced Treg cells. We used Foxp3.Cre.GFP 3
Rosa26.RFP (Figure 1C) and Foxp3.Cre.GFP 3 Rosa26.YFP
mice and saw no differences in the percentage of Treg and ex-
Foxp3 cells when the data were pooled from the different
lineage-tracer mice (Figure 1D). Equivalent to RFPYFP Tconv
cells, exFoxp3 cells were identified as expressing low to negative
amounts of GFP (Figures 1C and 1E). exFoxp3 cells made up a
higher proportion of MOG38-49-specific cells than polyclonal
cells at the preclinical stage of EAE in the LNs and spleen
8 days after immunization and at the peak stage of the disease
in the CNS (Figures 1C–1E). During EAE resolution, the propor-
tion of exFoxp3 cells in the MOG38-49-specific CD4
+ T cells
was higher than that of polyclonal CD4+ T cells in the LNs and
spleen but was similar to the proportion of polyclonal CD4+
T cells in the CNS (Figures 1C–1E). The MOG38-49-specific cells
had a larger fraction of Treg cells than polyclonal cells at all the
stages of EAE 7 days after immunization in the LNs and spleen,
as well as in the CNS, LNs, and spleen during the peak and
resolution of EAE. The ‘‘enrichment’’ of antigen-specific Treg
cells was in agreement with a previous study that demonstrated
that MOG38-49-specific Treg cell expanded from a Foxp3
hi Treg
cell population that existed in B6 mice prior to MOG immuniza-
tion (Korn et al., 2007). The kinetics of the exFoxp3 cells in
the MOG38-49-specific niche mirrored Treg cells at the preclin-
ical and peak stages of EAE, whereas the percentage of
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Figure 1. MOG38-49-Specific Treg Cells Downregulate Foxp3 during EAE
(A) Expression of GFP and RFP in lymph node (LN) and spleen CD4+ T cells of a 6-week-old B6 Foxp3.GFP.Cre.Rosa26.RFP mouse. Representative of 15
Foxp3.GFP.Cre.Rosa26.RFP or Foxp3.GFP.Cre.Rosa26.YFP mice. The percentages of Tconv (RFPFoxp3.GFP), Treg (RFP+ Foxp3.GFP+), and exFoxp3
(RFP+Foxp3.GFP) cells are indicated.
(B) High-affinity MOG38-49-specific T cells in the CD4
+ fraction were detected with I-Ab:tetramers at the indicated stages of EAE in LNs and spleen or the CNS
(spinal cord and cerebellum). Dot plots are gated on CD4+ T cells. Data are representative of three to six experiments.
(C) CD4+ T cells were gated on tetramer (polyclonal) (top) andMOG38-49-specific (bottom) cells and analyzed for the frequency of Tconv, Treg, and exFoxp3 cells
at the indicated stages of EAE in the LNs and spleen or the CNS. Data are representative of three to six experiments using Foxp3.GFP.Cre.Rosa26.RFP or
Foxp3.GFP.Cre.Rosa26.YFP mice.
(D and E) The proportions of Tconv, Treg, and exFoxp3 cells in MOG38-49-specific (filled square) and polyclonal (open circle) CD4
+ populations are shown in the
LNs and spleen (D) and the CNS (E) at the indicated stages of EAE. Data points are individual Foxp3.GFP.Cre.Rosa26.RFP or Foxp3.GFP.Cre.Rosa26.YFP mice,
and red lines show themean ± SEM. The percentage of each populationwas not significantly different in polyclonal versusMOG38-49-specific cells, as determined
with a paired t test. ND, not done.
See also Figure S1.
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Figure 2. Reduced Foxp3 Expression in
Antigen-Specific Treg Cells and Foxp3lo
Cells during EAE
(A) Ratio of GFP expression (MFI) in MOG38-49-
specific Treg cells versus polyclonal Treg cells.
Mean ± SEM of four to six mice per time point is
shown. p values are from an unpaired t test.
(B) Gating strategy for sort purification of LN and
spleen CD4+ T cell subsets 7 days after immuni-
zation with MOG35-55-CFA. Data are representa-
tive of three experiments.
(C) Post-sort analysis of GFP and RFP expression
in the sorted populations in (A).
(D) Post-sort analysis of intracellular (i.c.) Foxp3
and Foxp3-GFP levels in the sorted populations in
(A). ND, not done.
(E) Foxp3 expression was measured by quantita-
tive PCR and normalized to GAPDH. Each symbol
represents one mouse. Error bars represent the
mean ± SEM, and p values are from a two-tailed
unpaired t test.
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EAE resolution than during previous EAE stages, when the
percentage of MOG38-49-specific Treg cells continued to rise
(Figures 1D and 1E). The data suggest that antigen triggering
during inflammation induces antigen-specific Treg cells to accu-
mulate and downregulate Foxp3 to compose a major population
of exFoxp3 cells within the antigen-specific niche.
Treg Cells Downregulate Foxp3 Transcription
To gain insight into the precursor-product relationship of
MOG38-49-specific exFoxp3 cells during EAE, we analyzed952 Immunity 39, 949–962, November 14, 2013 ª2013 Elsevier Inc.Foxp3 expression in Tconv, Treg, and
exFoxp3 cells. According to studies using
Foxp3.GFP-Cre lineage-tracer mice,
Foxp3 expression is regulated at both
transcriptional and protein levels, which
allows for three readouts of Foxp3 regula-
tion (Bailey-Bucktrout and Bluestone,
2011). First, GFP is a direct readout of
Foxp3 transcription given that its expres-
sion is controlled by the Foxp3 locus pro-
moter and enhancer activity. Second, the
expression of YFP or RFPmarks cells that
currently express or historically ex-
pressed Foxp3. Third, the amounts of
Foxp3 reflect translation and protein turn-
over at the cellular level. Together, these
readouts allowed us to assess Foxp3
regulation in vivo. On the basis of median
(data not shown) or mean fluorescence
intensity (MFI), MOG38-49-induced Treg
cells had significantly lower levels of
Foxp3-driven GFP than did the polyclonal
Treg cells (Figure 2A), suggesting that the
entire population of MOG38-49-specific
Treg cells downregulated Foxp3 tran-
scription after antigen exposure and
inflammation.We next analyzed the expression of Foxp3 mRNA and Foxp3
in CD4+ T cell populations in the LNs and spleen during preclin-
ical EAE, when Foxp3-driven GFP was downregulated in Treg
cells. Foxp3mRNA and Foxp3were undetectable in sort-purified
RFPCD62LhiCD44 and CD62LloCD44+ ‘‘naive’’ and ‘‘effector-
memory’’ CD4+ Tconv cells, respectively (Figures 2B–2E). The
bulk population of RFP+ cells was subdivided into three subsets
on the basis of GFP expression. GFPhi Treg cells expressed the
highest levels of Foxp3 mRNA and Foxp3, whereas RFP+ cells
with lower levels of GFP expression (GFPlo cells) had significantly
lower amounts of Foxp3 mRNA than did GFPhi Treg cells
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subpopulation of 30%–40% cells that still expressed Foxp3,
although at lower levels than in GFPhi Treg cells (2,661 versus
4,534 MFI), but compared with GFPhi and GFPlo cells, they had
significantly downregulated Foxp3 mRNA (Figure 2E). The data
demonstrate that Foxp3-driven GFP faithfully reflects Foxp3
transcription during EAE and further suggest a hypothesis
wherein antigen-driven activation of Treg cells in an inflamma-
tory environment results in the downregulation of Foxp3 tran-
scription in bona fide Treg cells prior to loss of longer-lived
Foxp3. Once the residual Foxp3 is lost, Treg cells become func-
tionally unstable. Finally, the Foxp3+GFPRFP+ cells produce
IFN-g amounts similar to those of the Foxp3 population (data
not shown). Therefore, Foxp3 expression does not differentiate
this phenotype per se. This result is consistent with a previous
study (Ohkura et al., 2012).
Treg Cells Lose Foxp3
Recent studies have suggested that Treg cells are highly stable
under homeostatic conditions with high expression of IL-2Ra
and demethylated marks on the CpG motifs in the TSDR of the
Foxp3 locus (Miyao et al., 2012; Ohkura et al., 2012). To address
the hypothesis that instability is a function of exposure to an
inflammatory response, we examined Foxp3 expression in
antigen-specific Treg cells during the active autoimmune
response in EAE. Highly purified (>96%) Treg cells from naive
mice were transferred into mice during the onset of EAE and
were followed for changes in Foxp3. The Foxp3+ Treg cells ex-
pressed high amounts of CD25 and a fully demethylated TSDR
(Figures 3A and 3B) at the time of transfer. At the peak stage of
EAE (Figure 3C), we used a congenic mark to identify the trans-
ferred Treg cells in the CNS infiltrate and analyze Foxp3
expression in the MOG38-49-specific and polyclonal Treg cells
(Figure 3D). The majority of the transferred polyclonal Treg cells
in the CNS were stable for Foxp3 expression, given that 93.5%
retained Foxp3 (Figure 3E). In contrast, Foxp3 expression was
significantly lower in the adoptively transferred MOG-specific
Treg cells. In fact, Foxp3 was undetectable in 39% of
MOG38-49-specific Treg cells at the peak of CNS inflammation
(versus in <10% of the polyclonal Treg cells) (Figure 3D). It is
important to note that even the small loss of Foxp3 expression
within the polyclonal population could reflect antigen-driven
effects given that I-Ab:MOG38-49 tetramer staining does not
detect all the MOG-specific or other neural antigen-specific
Treg cells. These data formally demonstrate that a significant
percentage of Treg cells, defined by high levels of Foxp3 and
CD25 expression and a fully demethylated TSDR, lost Foxp3
after antigen exposure during an inflammatory response in vivo.
We demonstrated that Treg cells enriched with self-reactivity
are biased for loss of Foxp3 expression during an autoimmune
response, but the exFoxp3 cells that accumulate during EAE
(Figure 1) could also have developed in a subset of antigen-
specific cells with de novo Foxp3 expression as a result of anti-
gen priming. It has been suggested in epigenetic-tracing studies
that exFoxp3 cells arise from a Foxp3 T cell that transiently
expresses Foxp3 (Miyao et al., 2012). Peripherally induced and
in-vitro-induced CD4+ Treg cells, termed pTreg and iTreg cells,
respectively, that express Foxp3 during antigen recognition
in extrathymic compartments have been described as beingIunstable for Foxp3 expression and suppressor activity (Chen
et al., 2011; Josefowicz et al., 2012; Yadav et al., 2012). There-
fore, we addressed the possibility that exFoxp3 cells generated
during EAE arose from a Tconv cell population expressing Foxp3
for a transient but sufficient period of time to express Cre-recom-
binase and thus RFP. Congenically marked CD4+GFPRFP
cells were transferred into mice with active EAE and were fol-
lowed over time for determining whether CD4+GFPRFP+ cells
could develop within the antigen-specific Tconv cell population.
In four experiments, none of the MOG38-49
+ tetramer cells ex-
pressed RFP (Figure S2). Thus, only the transfer of GFP+RFP+
Treg cells into the inflamed EAE setting led to loss of GFP (i.e.,
GFPRFP+), whereas similar transfer of GFPRFP Tconv
cells did not result in a ‘‘transient’’ GFPRFP+ Tconv cell popu-
lation among the MOG-antigen-specific T cells. In contrast,
MOG38-49
+ exFoxp3 cells in the inflamed CNS at the peak of
EAE arose from Treg cells. Thus, although exFoxp3 cells
can be composed of populations of both uncommitted and
previously committed cells, in the context of an autoimmune
inflammatory response, such as EAE, the antigen-specific
Foxp3lo/ population is derived overwhelmingly from previously
committed, bona fide, Treg cells. These results are consistent
with the fact that MOG38-49-specific Foxp3
+ cells expanded
from an antigen-specific Treg cell population that existed prior
to autoimmunity, as well as with the fact that MOG38-49-specific
exFoxp3 cells were derived from an established Treg cell popu-
lation and not transient Foxp3-expressing cells.
MOG38-49-Specific and Polyclonal exFoxp3 Cells in the
CNS Are Differentially Demethylated at the TSDR
Next, we examined the methylation status of CpG motifs in the
TSDR of the Foxp3 locus (Huehn et al., 2009). Previous studies
have shown that Treg cells exhibit demethylated CpG sites in
the TSDR, whereas the CpG sites in this intron are fully methyl-
ated in the overwhelming majority of Tconv cells and pTreg cells
with unstable or transient Foxp3 expression (Floess et al., 2007;
Haribhai et al., 2011; Ohkura et al., 2012).
Using an assay developed for low cell numbers (Figure S3), we
determined the TSDR methylation status in polyclonal and
MOG38-49-specific Tconv, Treg, and exFoxp3 cells in the CNS
at the peak of EAE. As expected, both polyclonal and
MOG38-49-specific RFP
Foxp3.GFP Tconv cells were fully
methylated at the TSDR, and both polyclonal and MOG38-49-
specific RFP+Foxp3.GFPhi Treg cells were fully demethylated
at the TSDR (Figure 4). TheMOG38-49-specific RFP
+Foxp3.GFP
exFoxp3 cells in the CNS at the peak of EAE were more deme-
thylated at the TSDR than the polyclonal exFoxp3 cells at the
same location (Figure 4). In addition, the TSDR was predomi-
nantly demethylated in MOG38-49-specific exFoxp3 cells from
the CNS in two out of three mice. Thus, these data support the
hypothesis that Treg cells with a fully demethylated TSDR can
lose Foxp3 expression and become exFoxp3 cells.
Autoreactive exFoxp3 Cells Produce Potentially
Pathogenic Cytokine
T effector cells in the CNS of mice with EAE produce cytokines,
including IFN-g and IL-17A (Ivanov et al., 2006), that induce a
cascade of inflammatory cell recruitment, glial cell activation,
and death of myelin-producing oligodendrocytes and theirmmunity 39, 949–962, November 14, 2013 ª2013 Elsevier Inc. 953
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Figure 3. MOG-Specific exFoxp3 Cells Are Generated from Foxp3hi Treg Cells
(A) Foxp3 and CD25 staining of sort-purified CD45.1+CD4+CD25hiGITRhi Treg cells.
(B) CpG demethylation status of the TSDR in the CD45.1+ Treg cells depicted in (A). The location of each CpG in the Foxp3 locus is depicted.
(C) EAE scores of mice that received two million Treg cells depicted in (A) and (B) (circle) and untransferred mice (square). Data represent the mean ± SEM of four
mice per group. The EAE score between the groups at each time point was not significantly different in a paired t test. The difference between the groups was not
significant.
(D) At day 16 of EAE, as depicted in (C), CNS cells were isolated and Foxp3 intracellular (i.c.) staining shown in CD45.1+CD4+ gated cells. Data are representative
of four mice.
(E) Percentage of Foxp3 loss in polyclonal (unfilled bar) and MOG38-49-specific (filled bar) CD45.1
+ transferred Treg cells in the CNS at the peak of EAE. Individual
mice and pooled data (mean ± SEM) are shown. p values are from an unpaired t test.
See also Figure S2.
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producing, and thus potentially pathogenic, T cells might be
derived from the MOG-specific exFoxp3 population, we exam-954 Immunity 39, 949–962, November 14, 2013 ª2013 Elsevier Inc.ined the production of IFN-g by Tconv and lineage-tracer-
positive cells isolated from the CNS afterMOG35-55 antigen recall
in vitro. During the peak of EAE, 3.4% of the exFoxp3 cells
e e e
Figure 4. Distinct TSDR CpG Demethylation Marks in Autoreactive and Polyclonal exFoxp3 Cells in the CNS during EAE
Percent demethylated TSDRCpGmotifs in sort-purifiedMOG38-49-specific (filled bar) and polyclonal (open bar) CD4
+RFP Tconv, CD4+ RFP+ Foxp3.GFP+ Treg,
and CD4+RFP+ Foxp3.GFP exFoxp3 cells infiltrating the CNS at the peak of EAE. The results of three analyzed mice are shown.
See also Figure S3.
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response to MOG35-55 stimulation, this percentage increased
to 9.6% of the exFoxp3 cells, only slightly lower than the
11.6%of Tconv cells that produced IFN-g in the same conditions
(Figures 5A and 5B). IFN-g production was never detected in
antigen-stimulated Foxp3+ Treg cells during EAE. Interestingly,
IL-17A was undetectable in exFoxp3 T cells in this assay and
was detected only after PMA and ionomycin stimulation (data
not shown). Therefore, Foxp3 loss bestows MOG-specific Treg
cells with IFN-g production levels comparable to those of path-
ogenic T effector cells, which has also been observed in the
diabetes setting (Zhou et al., 2009). These results further argue
against the hypothesis that exFoxp3 cells are derived from a
transient Foxp3-expressing population given that others have
shown that these cells are marked by coexpression of Foxp3
and RORgt, the lineage-specific transcription factor for the IL-
17-producing T helper 17 (Th17) cell subset (Zhou et al., 2008a).
exFoxp3 Cells Are Pathogenic, Causing EAE
In EAE, pathogenic T cells induce an inflammatory cell infiltrate in
the spinal cord and cerebellum, resulting in tail and hind-limb
dysfunction (Bailey et al., 2006). MOG35-55-reactive CD4
+ Tconv
and exFoxp3 cells produced equivalent levels of IFN-g in the
CNS at peak (Figure 5), suggesting that they might be patho-
genic. The implication that Treg cell instability leads to pathoge-
nicity in autoimmunity is of major significance because Treg cells
are enriched with self-reactivity (Hsieh et al., 2006; Wong et al.,
2007) and can express homing receptors to allow preferential
migration to inflamed tissues (Dominguez-Villar et al., 2011;
Josefowicz et al., 2012). To test the pathogenicity of exFoxp3
cells in EAE, we compared isolated exFoxp3 cells with Tconv
and Treg cells to determine their ability to induce EAE after
adoptive cell transfer. Congenically marked CD4+RFPIFoxp3.GFP Tconv, CD4+ RFP+ Foxp3.GFP+ Treg, and
CD4+RFP+ Foxp3.GFP exFoxp3 cells were purified from the
LNs and spleen of MOG35-55-CFA-immunized mice by fluores-
cence-activated cell sorting and expanded in vitro with
MOG35-55 for enriching antigen-reactive cells, then with anti-
CD3 plus anti-CD28 polyclonal stimuli for generating enough
cells for the experiment. Expansion was performed with IL-2
for Tconv and Treg cells and with IL-2 and IL-7 for exFoxp3 cells.
IL-7 was needed for expanding exFoxp3 cells ex vivo, most likely
because they express low levels of CD25 (IL-2Ra) and express
CD127 (IL-7Ra) at higher levels (Zhou et al., 2009). No Th1- or
Th17-cell-driving cytokines that might influence the effector
function of the T cells were added. The individual cell populations
remained stable for Foxp3.GFP expression during the expansion
and were resorted to purify from feeder cells during the antigen-
driven expansion (Figure S4). Individual cell populations were
transferred into lymphodeficient recipients, which were immu-
nized with MOG35-55-CFA for inducing EAE. Immunization was
necessary for inducing EAE because the cells were expanded
in ‘‘neutral’’ conditions, and no population induced EAE without
immunization. As expected, Treg cells did not induce EAE,
whereas MOG-specific exFoxp3 and Tconv cells induced EAE
with similar incidence and severity (Figures 6A and 6B). The
onset of disease was slightly delayed in exFoxp3 cell recipients
compared to Tconv cell recipients in the experiment depicted,
but the difference was not significant when the experiments
were pooled (data not shown). Infiltrates were isolated from the
spinal cord and cerebellum (CNS) of recipients at the peak of
EAE (Figure 6A), and the abundance and composition of the
inflammatory cells were compared. The transferred exFoxp3
cells had a stable RFP+GFP phenotype after the induction of
EAE, and the majority of Tconv cells remained RFP, although
4.7% transiently expressed Foxp3 (Figure S4). This transientmmunity 39, 949–962, November 14, 2013 ª2013 Elsevier Inc. 955
γγ+
 (%
) 
A
B
Figure 5. CNS exFoxp3 Cells Produce IFN-g Similarly to Tconv Cells
(A) CNS cells were isolated at the peak of EAE and incubated for 16 hr with MOG35-55, and Tconv, Treg, and exFoxp3 cell subsets were identified on the basis of
staining for CD4, YFP or GFP, and Foxp3. IFN-g (tinted histogram) and isotype control (dashed line) staining in the live CD4+ population is shown. Data are
representative of three experiments.
(B) Percentage of CNS CD4+ T cells expressing IFN-g as in (A) with (filled bar) or without (open bar) MOG35-55 stimulation in vitro. Data represent the mean ± SEM
of three experiments with two to three mice pooled in each.
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lymphodeficient environment is in agreement with previous
studies (Miyao et al., 2012). The numbers of macrophages
(CD45hi, CD11b+, CD11c), myeloid dendritic cells (mDCs;
CD45hi, CD11b+, CD11c+), plasmacytoid dendritic cells
(pDCs; CD45hi, CD11b, CD11c+, CD45R+), microglia (CD45med,
CD11b+), and T cells in the CNS after EAE induction with Tconv
or exFoxp3 cells were similar (Figure 6C), demonstrating that
Tconv and exFoxp3 cells orchestrate similar cellular immune
responses during autoimmunity. The majority of Tconv and
exFoxp3 cells in the inflamed CNS produced IFN-g (Figure 6D),
which could have initiated the inflammatory cascade that caused
EAE in the recipients. These results demonstrate that exFoxp3
cells can function as pathogenic effector cells producing IFN-g
in the CNS and that MOG-specific exFoxp3 cells induce EAE
similarly to Tconv cells.
IL-2R Signaling Overrides Foxp3 Instability
IL-2 is critical for expression of Foxp3 in Treg cells and the
homeostasis of Treg cells in the periphery. It has been previously
shown that targeting IL-2 to Treg cells with low concentrations of
IL-2-anti-IL-2 complexes prevents or reverses autoimmune
diabetes and delays onset and severity of EAE by causing Treg956 Immunity 39, 949–962, November 14, 2013 ª2013 Elsevier Inc.cell expansion (Tang et al., 2008; Webster et al., 2009). We
hypothesized that supplementing antigen-experienced Treg
cells with exogenous IL-2 would stabilize Foxp3 expression in
MOG-specific Treg cells and would thus prevent the de novo
generation of exFoxp3 cells. Treatment with IL-2-anti-IL-2
complexes after immunization induced a unimodal increase in
phosphorylated STAT5 levels in Treg cells but did not affect
phosphorylated amounts of STAT5 in Tconv cells or the majority
of exFoxp3 cells (Figure S5). IL-2-anti-IL-2 complex treatment
resulted in a significant reduction in the proportion and number
of MOG38-49-specific Treg cells that lost Foxp3 expression and
became exFoxp3 cells, but it did not affect the abundance of
polyclonal exFoxp3 cells (Figures 7B–7D), which is consistent
with the absence of phosphorylated STAT5 in these cells in
response to treatment (Figure S5). As expected, there was a
trend toward increased numbers of MOG38-49-specific and
polyclonal Treg cells (Tang et al., 2008; Webster et al., 2009);
however, it was striking that the only significant difference was
stabilized Foxp3 expression inMOG38-49-specific Treg cells after
treatment with IL-2-anti-IL-2 complexes (Figure 7). We conclude
that Treg cell expansion does not result in Foxp3 instability per se
because the increase in number of MOG38-49-specific Treg cells
did not result in increased numbers of exFoxp3 cells but rather a
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Figure 6. exFoxp3 Cells Cause EAE
(A) The proportion of mice that developed
EAE after transfer of CD4+RFPGFP Tconv,
RFP+GFP+ Treg, and RFP+GFP exFoxp3 cells.
Data were pooled from two experiments with three
mice per group and represent the mean ± SEM.
(B) EAE clinical score of mice that developed EAE
as described in (A) in one of two experiments.
(C) The number of the indicated inflammatory cell
populations in the spinal cords of mice shown in
(B). Data are representative of two experiments.
(D) Staining and percentage of IFN-g in CNS T cells
from (B).
See also Figure S4.
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that Foxp3 instability in Treg cells responding to in vivo antigen is
IL-2 sensitive. In a previous study, Webster et al. (2009) treated
EAE prophylactically with IL-2 complexes to protect from dis-
ease; the conclusion was that the IL-2-expanded polyclonal
Treg cells suppressed the development of the autoreactive
effector T cell response during priming for EAE. The goal of our
experiments was to target Treg cell instability, which, given the
enrichment of MOG38-49-reactive exFoxp3 cells compared with
polyclonal cells, occurred within the initial 7 days after EAE
induction (Figures 1C and 1D). Treg cells were targeted with
IL-2-anti-IL-2 complexes in the 3 days after EAE induction, the
MOG38-49-reactive Treg cells retained high levels of Foxp3
expression, and the mice were protected from disease
(Figure 7G), suggesting that the stability of antigen-specific
Treg cells might be important for the course and control of
autoimmunity.
DISCUSSION
Using lineage reporter and ‘‘fate-mapping’’ mice to characterize
Foxp3 expression and downregulation within the same cell over-
time, we previously showed that a subset of cells expressing
Foxp3 could become Foxp3lo (exFoxp3 cells), and previousImmunity 39, 949–962, Nstudies by our group (Zhou et al., 2009)
have led to the hypothesis that a subset
of Treg cells could demonstrate highly
reduced levels of Foxp3 and become
functionally unstable in the context of
autoimmunity and inflammation. How-
ever, this interpretation has been chal-
lenged by other studies, which concluded
that ‘‘terminally differentiated’’ Treg cells
are stable and exFoxp3 cells would
instead derive from loosely committed
Treg cells that have not fully acquired
many features of bona fide Treg cells,
such as high amounts of Foxp3 and
CD25 and demethylation at the TSDR
(Rubtsov et al., 2010; Miyao et al.,
2012). Here, we address these apparently
contradictory results in a model of auto-
immunity by demonstrating that loss of
Foxp3 and the resulting instability dooccur in bona fide Treg cells but predominantly in a subset of
self-antigen-specific Treg cells during responses initiated by
immunization with this self-antigen. There is indeed evidence
of a percentage of exFoxp3+ cells derived from cells transiently
expressing Foxp3, but these cells are not derived from the
autoantigen-specific T cell population induced during EAE.
Rather, the Treg cells followed in this autoimmune setting
expressed high amounts of CD25 and had a demethylated
TSDR, markers that identify Treg cells that in the steady state
maintained high levels of Foxp3 expression under lymphoreplete
conditions in other studies (Miyao et al., 2012; Rubtsov et al.,
2010). However, these studies were largely performed in the
steady state and under a homeostatic setting where the immune
system had not been perturbed by autoimmunity. Importantly,
these studies did not focus on selective, antigen-specific Treg
cells expanded in response to an inflammatory autoimmune
reaction. We addressed whether committed Treg cells lose
Foxp3 during a mouse model of autoimmunity, EAE, by interro-
gating antigen-specific Treg cells within the polyclonal reper-
toire. Using lineage tracing and cell transfers, we found that
although the majority of polyclonal and antigen-specific Treg
cells stably expressed Foxp3 during the autoimmune response
in this mouse model of autoimmunity, a substantial fraction
of antigen-specific Treg cells with ‘‘signature’’ features (Foxp3hi,ovember 14, 2013 ª2013 Elsevier Inc. 957
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Figure 7. IL-2 Stabilizes Foxp3 during EAE
(A) Foxp3.GFP levels in polyclonal and MOG38-49-specific CD4
+RFP+ T cells from LNs and spleen 6 days after EAE induction and treatment with IL-2-anti-IL-2
complex or saline control on days 1, 3, and 5.
(B–F) Abundance of CD4+ T cell populations in LNs and spleen from mice receiving saline or IL-2-anti-IL-2 complex treatment as in (A). (B) Percentage of
RFP+GFPexFoxp3+ cells in MOG38-49-reactive cells. (C) Frequency of MOG38-49-reactive RFP
+GFPexFoxp3+ cells. (D) Frequency of polyclonal
RFP+GFPexFoxp3+ cells. (E) Frequency of MOG38-49-reactive RFP
+GFP+ Treg cells. (F) Frequency of polyclonal RFP+GFP+ Treg cells. Each point represents
one sample, and lines represent the mean ± SEM of the pooled data. p values are from two-tailed t tests.
(G) EAE course with IL-2-anti-IL-2 complex treatment on days 1, 3, and 5. Triangles depict control (saline)-treated animals, and squares represent IL-2-treated
animals. Data represent the mean ± SEM from two experiments with five animals in each.
See also Figure S5.
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tion, lost Foxp3, and acquired effector T cell characteristics
such as IFN-g production and pathogenic potential in vivo. It
should be highlighted that the exFoxp3 cells were only apparent
in adoptive transfer experiments where bona fide CD4+CD25hi
Treg cells with a demethylated TSDR were transferred into
mice with ongoing EAE. In some animals, up to one-third of958 Immunity 39, 949–962, November 14, 2013 ª2013 Elsevier Inc.the MOG tetramer+ antigen-specific Treg cells lost Foxp3 ex-
pression. In contrast, transfer of highly purified CD4+GFP
RFP Tconv cells did not result in any antigen-specific exTreg
cells, suggesting that this population did not derive from a differ-
entiating transient Foxp3+ subset. These findings link Foxp3
instability in an antigen-specific subset of Treg cells to patho-
genic responses during autoimmunity. In this regard, circulating
Immunity
Treg Cell Instability during Autoimmune AttackTreg cells that have altered characteristics including reduced
suppressive ability, production of IFN-g, and other features of
Th1 cells are enriched in type 1 diabetes and multiple sclerosis
in humans (Dominguez-Villar et al., 2011; McClymont et al.,
2011). Interestingly, stable Foxp3 expression resumed during
the remission phase of disease or after treatment with IL-2-anti
IL-2 complexes that also ameliorate disease, suggesting poten-
tial therapeutic opportunities in these areas.
Even in the inflamed setting, a large number of MOG38-49-
specific Treg cells retained high amounts of Foxp3. This most
likely reflects positive feedback of Foxp3 on its own expression
(Zheng et al., 2010), and we hypothesize that once a low
threshold of Foxp3 transcription is reached, the Treg cell tran-
scriptional landscape is lost and characteristics of exFoxp3 cells
(e.g., loss of Foxp3 and acquisition of IFN-g expression) become
apparent (Zheng et al., 2007). Induced Treg cells or loosely
committed Foxp3+ cells are prone to Foxp3 instability and
demonstrate a failure to imprint stable epigenetic marks at the
Foxp3 locus (Haribhai et al., 2011; Josefowicz et al., 2012,
Ohkura et al., 2012). We thus investigated whether the Treg cells
that downregulate Foxp3 transcription during EAE might be
predisposed because of a methylated TSDR. In two out of three
mice, Foxp3 downregulation occurred predominantly in antigen-
specific Treg cells with a demethylated TSDR, suggesting that
lack of epigenetic imprinting in this region of the Foxp3 locus is
not a leading cause of loss of Foxp3 expression in Treg cells
during EAE. In the third mouse, the antigen-specific exFoxp3
cells had a methylated TSDR, suggesting that the exFoxp3 cells
derived from loosely committed Treg cells perhaps as a conse-
quence of the local inflammatory environment, as previously
reported (Miyao et al., 2012). Thus, exFoxp3 cells derive from
bona fide Treg cells and loosely committed cells in individual
mice, which could reflect differences in the local milieu that influ-
ence lineage differentiation and stability at the population level.
The TSDR data further suggest that themajority of polyclonal ex-
Foxp3 cells arise from transient or unstable Foxp3 expression
(Miyao et al., 2012). The factors inducing Foxp3 instability in a
subset of antigen-specific Treg cells remain unclear. Low
CD25 expression and a loss of STAT5-driven Foxp3 expression
have been implicated in Foxp3 instability during homeostasis
(Miyao et al., 2012), but this does not appear to be the case in
the generation of MOG-specific exFoxp3 cells during EAE.
Treg cells responded to the IL-2 administered with unimodal
phosphorylation of STAT5, suggesting that Treg cells are able
to respond to IL-2 during EAE. Rescue of Foxp3 expression
with IL-2-anti-IL-2 complexes suggests a deficiency in IL-2 avail-
able to Treg cells in vivo. Treg cells compete with T effector cells
for local IL-2 during an immune response (O’Gorman et al.,
2009), which is required for efficient Treg cell homeostasis (Bar-
ron et al., 2010; Zorn et al., 2006). The development of a strong
effector cell response that consumes IL-2 might tip the balance
of stability in Treg cells responding to antigen in a microenviron-
ment with T effector cells. Consistent with this hypothesis, other
studies have shown that Treg cell instability occurs during strong
Th1-polarized responses (Oldenhove et al., 2009; Takahashi
et al., 2011), and IL-2 deficiency has been implicated in one
study (Oldenhove et al., 2009). IL-2-anti-IL-2 complex stabiliza-
tion of Foxp3 in Treg cells correlated with reduced CNS inflam-
matory disease, further supporting that Treg cell instability isIdetrimental for tissue-specific tolerance. In this regard, autoim-
mune diabetes has also been associated with a local deficiency
in Treg-cell-mediated immunoregulation and low Foxp3 expres-
sion in islet-infiltrating Treg cells (Tang et al., 2008; Zhou et al.,
2009). Moreover, IL-2 therapy restored Foxp3 expression in
pancreatic Treg cells and could prevent or cure new-onset
diabetes in NOD mice (Grinberg-Bleyer et al., 2010; Tang et al.,
2008), suggesting that local deficits in IL-2 signaling might be a
general mechanism leading to downregulation of Foxp3 and
Treg cell instability in autoimmune diseases.
Our data suggest that Foxp3 instability in Treg cells is
induced and pronounced after antigen triggering and during
inflammatory responses. Treg cell stability mirrors the resolu-
tion of autoimmune inflammatory disease. It is tempting to
speculate that Treg cell stability drives the regulation of autoim-
mune responses. Recent studies of antigen-specific Treg cells
have demonstrated a rapid expansion of Treg cells with a sec-
ond wave of antigen availability (Rosenblum et al., 2011, Rowe
et al., 2012). In line with a ‘‘priming and memory’’ model for
Treg cells, we have shown that Treg cell instability occurs dur-
ing the acute phases of inflammation, and this could remove
inefficient, unstable Treg cells from the pool. The stable Treg
cells that remain might be better equipped to control further
flares of inflammation; indeed, Treg cell stability correlated
with EAE resolution. We determined that the frequency of
MOG-specific exFoxp3 cells declined during the peak and res-
olution phases and increased in the peripheral LNs during the
same time frame. It is possible that the unstable Treg cells
emigrate from the CNS during the decline of inflammation
and take up residence in the secondary LN organs, as do
effector cells during relapsing remitting EAE, although they
have no further pathogenic consequence to the progression
of the disease (Vanderlugt et al., 2000). Thus, instability at the
individual cell level in a subset of Treg cells could be followed
by improved stability and regulation at the population level in
certain circumstances.
Treg-cell-derived MOG-specific exFoxp3 cells presented an
effector cell phenotype with IFN-g production and pathogenic
potential after restimulation with their cognate antigen in vitro
or in vivo. Although exFoxp3 cells are 10% of the frequency of
Tconv cells that produce IFN-g in the CNS during EAE, the local
production of IFN-g can provide amplifying feedback on local
conventional Th1 cells (Takahashi et al., 2011). Indeed, exFoxp3
cells producing IFN-g cause EAE with a severity similar to that of
Tconv cells. Teleologically, it is possible that Foxp3 instability
during normal immune responses could aid the generation of
an antipathogen response, and an increase in protective cyto-
kine production early in the response could provide a boost to
protective immunity. However, as highlighted in this study, loss
of Foxp3 correlates with, and might contribute to, the develop-
ment of autoimmunity. Treg cell therapies are being tested in
clinical trials in type 1 diabetes and GVHD, raising concerns
that Treg cell instability could lead to unwarranted effects in
patients and indicating that additional studies will be needed
for determining the factors leading to instability. Moreover,
Treg cell therapy might require the cover of a stabilizing factor
such as IL-2, which has been used for directly modulating the
frequency and proliferation of Treg cells in patients (Long et al.,
2012; Koreth et al., 2011; Zorn et al., 2006).mmunity 39, 949–962, November 14, 2013 ª2013 Elsevier Inc. 959
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Mice
Foxp3.GFP-Cre.ROSA26-YFP reporter mice have been described previously
(Zhou et al., 2009) and were backcrossed greater than eight generations
onto the B6 background. For the generation of new lineage reporter mice
that had less spectral overlap than GFP versus YFP, allowing improved
purification by flow cytometric sorting, B6 Foxp3.GFP-Cre mice (Zhou et al.,
2009) and Foxp3.YFP.Cre mice (Rubtsov et al., 2008) were crossed with B6
ROSA26-RFP reporter mice (Luche et al., 2007). B6 TCRa/ mice were ob-
tained from Jackson Laboratories. All mice were housed and bred under spe-
cific pathogen-free conditions at the University of California, San Francisco
Animal Barrier Facility. The Institutional Animal Care and Use Committee of
the University of California, San Francisco approved all animal experiments.
Antibodies
Labeled antibodies specific to CD4 (RM4-5), CD8 (Ly-2), CD25 (PC61), GITR
(DTA-1), CD44 (pgp-1), FoxP3 (FJK-16 s), IL-17A (eBio17B7), IFN-g (XMG1.2),
phosphorylated STAT5 (pY694), and specific isotype controls were purchased
from BD PharMingen or eBioscience. Intracellular GFP or YFP was stained
with anti-GFP (rabbit polyclonal eBioscience catalog no. 14-6774-81) and
Fab’2 anti-rabbit (goat polyclonal eBioscience catalog no. 11-4839-81).
Flow Cytometry
Stained single-cell suspensions were analyzed with a LSRII flow cytometer
running FACSDiva (BD Biosciences), and FSC 2.0 files were analyzed and
presented with FLOWJO Software (TreeStar). T cells were sorted with a MoFlo
high-speed cell sorter (DakoCytomation) or FACSAria (BD Biosciences).
Phosphorylated STAT5 Flow
Spleen cells were harvested directly into fixative for ex vivo analysis of STAT5
phosphorylation, and staining was performed as described in O’Gorman et al.
(2009).
Induction of EAE
B6 mice were immunized subcutaneously with 100 ml of emulsified CFA
(BD Difco) supplemented with 4 mg/ml Mycobaterium tuberculosis H37Ra
(BD Difco) and 200 mg MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK,
Genemed Synthesis) and received intraperitoneal injections of 200 ng
pertussis toxin from Bordetella pertussis (Sigma Aldrich) at the time of immu-
nization and 48 hr later. Clinical disease was assessed by the scoring of
ascending hind-limb paralysis as follows: no signs, score 0; flaccid tail, score 1;
hind-limb weakness, score 2; partial hind-limb paralysis, score 3; complete
hind-limb paralysis, score 4; and moribund mouse, score 5.
Transfer of CD4+ Treg and Tconv Cells into EAE for Tracking Foxp3
Stability
Donor mice congenic for CD45.1 were immunized with MOG35-55 peptide
emulsified in CFA similar to EAE induction; no pertussis toxin was adminis-
tered. Five days after immunization, Treg cells were sort purified from axillary,
inguinal, and brachial LNs and spleen and were gated as CD45.1+, CD4+,
CD25hi, or GITRhi. For Foxp3-lineage tracing of Tconv cells, CD45.1+
CD4+GFPRFP T cells were sort purified from axillary, inguinal, and brachial
LNs and spleen 5 days after immunization of Foxp3.GFP.RFP reporter mice. A
total of 2 3 106 CD45.1+ Treg cells or CD4+ Tconv cells were transferred
intravenously into CD45.2 mice at the onset of EAE. At the peak of EAE, the
CD45.1+ transferred cells were analyzed for MOG-tetramer staining in the
CNS as described below.
CD4+ Tconv, Treg, and exFoxp3 Cell Expansion and Adoptive
Transfer for EAE
Eight days after EAE induction in Foxp3-GFP.RFP reporter mice, CD4+ T cell
populations were sort purified from axillary, inguinal, and brachial LNs and
spleen. Viable T cells were gated as CD4+ cell, Treg cells were gated as
GFP+ RFP+ cells, exFoxp3 cells were gated as GFPRFP+ cells, and Tconv
cells were gated as GFPRFP cells. T cells were cultured at 2 3 105 cells/ml
plus five times the number of lethally irradiated congenically marked spleno-
cytes as feeder cells, 20 mg/ml MOG35-55, and growth-factor cytokines: Tconv960 Immunity 39, 949–962, November 14, 2013 ª2013 Elsevier Inc.cells, 100 U/ml IL-2; Treg cells, 2,000 U/ml IL-2; and exFoxp3 cells, 2,000 U/ml
IL-2 and 10 ng/ml IL-7. Growth-factor cytokines were refreshed every 2 days
for 11 days. Cells were replated at 23 105 cells/ml and polyclonally expanded
for 7 days with 1:1 bead:cell T-activator CD3/CD28 beads (Dynabeads,
Life Technologies) and growth-factor cytokines as above. After 7 day, viable
CD4+ T cells were resorted for transfer as described above and shown in
Figure S4. Sublethally irradiated (350 rads) B6 TCRa/ mice received
350,000–500,000 T cells intravenously. Recipients were immunized with
MOG35-55-CFA on the day of cell transfer and 7 days later. Mice were scored
for EAE in a blind fashion every 2 days.
IL-2-Anti-IL-2 Complex Treatment
Mice immunized for EAE received an intraperitoneal injection of 1.5 mg
recombinant mouse IL-2 (eBioscience) complexed with 5 mg anti-IL-2 (clone
JES6-1A12, eBioscience) for 15 min at 37C on days 1, 3 and 5.
MHC II Tetramer Staining
I-Ab:MOG38-49 and I-A
b:hClip tetramers were provided by the National
Institutes of Health Tetramer Core Facility. CNS samples were stained
with tetramer and analyzed directly, whereas tetramer-labeled LN and spleen
samples were enriched for analysis as previously published (Moon et al.,
2007).
TSDR Methylation Analysis
Methylation at the TSDR was evaluated by sequencing as described in Zhou
et al., (2009) and by quantitative PCR (qPCR) as described in Yadav et al.
(2012).
Foxp3 qPCR
To assay endogenous Foxp3 transcription, we used a qPCR probe that
recognizes a sequence in Foxp3’s tenth exon, which is not expressed by the
BAC-Foxp3.GFP-Cre construct because it expresses a stop codon in exon
1 (Zhou et al., 2008b). RNA was isolated by TRIzol (Life Technologies), and
cDNA was obtained with a first-strand cDNA synthesis kit (GE Healthcare
Biosciences). qPCR was performed with TaqMan gene expression assays
(Mm 00475165-m1, Life Technologies, Applied Biosystems) and analyzed
with a 7500 Fast real-time PCR system.
Isolation of CNS Leukocytes
Mice were sacrificed with CO2 and immediately perfused through the left
ventricle with PBS until the effluent ran clear. Spinal cords were extruded
by flushing of the vertebral canal with PBS, and cerebella were removed.
Spinal cords and cerebella were diced, placed in Hank’s balanced salt
solution (HBSS) containing 25 mM HEPES, 300 Wunsch units/ml type-D
clostridial collagenase (Life Technologies), and 50 mg/ml DNase I (Roche),
and incubated for 30 min (37C). The homogenate was resuspended in 30%
isotonic Percoll (Pharmacia), underlaid with 70% Percoll, and centrifuged at
1,160 g at room temperature for 30 min. Mononuclear cells were collected
from the Percoll interphase and washed twice in HBSS containing 2% fetal
calf serum.
Cytokine Production
CNS mononuclear cells were incubated at 5 3 106 cells/ml with 1 mg/ml
anti-CD28 (PV-1) with or without 10 mg/ml MOG35-55 for 16 hr at 37
C. Cells
were activated for 2.5 hr with 50 ng/ml phorbol 12-myristate 13-acetate and
2 mM monensin before labeling with LIVE/DEAD fixable dead stain (Life
Technologies), staining for CD11b (dump), CD4, Foxp3, IFN-g, and GFP or
YFP, and flow cytometric analysis.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and can be found with this
article online at http://dx.doi.org/10.1016/j.immuni.2013.10.016.
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